Febuxostat Tablets Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets
Available Strengths: 40 mg, 80 mg
Reference Brands: Uloric(EU & US)
Category: Arthritis
Febuxostat inhibits xanthine oxidase, reducing uric acid production. It effectively lowers serum uric acid levels, preventing gout attacks and urate crystal formation. Benefits include improved uricemia management, decreased gout flare frequency, and enhanced quality of life with a favorable safety profile when used appropriately. Febuxostat tablets is available in Oral Tablets and strengths such as 40 mg, 80 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Febuxostat tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Febuxostat tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Febuxostat tablets are approved in the EU and US for managing hyperuricemia and gout. In the EU, brands like Uloric (by Takeda) are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval relies on extensive clinical data and biosimilarity evaluations. Both regions require detailed dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for febuxostat tablets, ensuring adherence to European and American standards, helping you navigate complex regulatory landscapes seamlessly for safe, effective gout management.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Febuxostat is used to lower uric acid levels in the blood and prevent gout attacks in adults. Gout occurs when there is a buildup of uric acid crystals in the joints, leading to inflammation and pain. Febuxostat helps by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid, thereby reducing its levels and preventing crystal formation.
Febuxostat is made from the active ingredient febuxostat, a non-purine selective xanthine oxidase inhibitor. Its chemical composition is 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid, along with inactive ingredients such as lactose monohydrate, microcrystalline cellulose, and magnesium stearate (depending on the formulation).
The most common trade names of Febuxostat are
Febuxostat (Uloric) is manufactured by
The generic name of the drug is
Brand names include
Febuxostat is manufactured in multiple regions, including
Related Products
Pegloticase Injecatble
Strength:
8 mg/1.2 mL vial
Form: Injectable (IV solution)
Reference Brands: Krystexxa (US)
View Details
Allopurinol Tablets
Strength:
100 mg, 300 mg
Form: Oral Tablets
Reference Brands: Aloprim(US & EU)
View Details
Triamcinolone Injectable (Im, Intra-Articular)
Strength:
40 mg/mL, 80 mg/mL, 80 mg/2 mL
Form: Injectable (IM, intra-articular)
Reference Brands: Kenalog(US & EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
